Crystalline ppar-delta agonist
AssigneeReneo Pharmaceuticals, Inc.
InventorsSusana DEL RIO GANCEDO, Osama SULEIMAN, Emma SHARP, Cristina BALOGH, Rachael LEE, Julie MACRAE, Neil FEEDER
Life of this patent
Estimating the term…
Abstract
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Claims17
Crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate (Compound II), wherein crystalline Compound II is crystalline Form 1, characterized as having:
- (a) an XRPD pattern as shown in FIG. 1;
- (b) an XRPD pattern with peaks at about 2.8_° 2-Theta, about 7.2° 2-Theta, about 13.4° 2-Theta, about 17.8° 2-Theta, about 19.7° 2-Theta, about 19.9° 2-Theta, and about 20.6° 2-Theta as measured using Cu Kα radiation;
- (c) a DSC thermogram as shown in FIG. 2;
- (d) a DSC thermogram with an endotherm having onset at about 179.5° C. and peak at about 181.6° C.;
- (e) a TGA pattern as shown in FIG. 3;
- (f) a TGA pattern with a 0.1% w/w loss from 25 to 60° C. and degradation onset at about 250° C.;
- (g) an FTIR spectroscopy pattern as shown in FIG. 4;
- (h) an FTIR spectroscopy pattern with peaks at about 103 cm−1, about 838 cm−1, about 1220 cm−1, about 1504 cm−1, and about 1612 cm−1;
- (i) a Raman spectroscopy pattern as shown in FIG. 5;
- (j) a Raman spectroscopy pattern with peaks at about 103 cm−1, about 126 cm−1, about 810 cm−1, about 1158 cm−1, about 1238 cm−1, about 1604 cm−1, and about 1629 cm−1;
- (k) unit cell parameters equal to the following at 100 K:
- Crystal System
- Monoclinic
- Space Group
- P2/c
- a (Å)
- 31.581(3)
- b (Å)
- 6.1180(4)
- c (Å)
- 27.2046(18)
- α°
- 90
- β°
- 94.447(7)
- γ°
- 90
- V (Å3)
- 5240.4(7)
- Z
- 8
- Calculated Density
- 1.363
- (Mg/m3)
- Absorption
- 0.937
- coefficient (mm−1)
- F(000)
- 2256
- or
- (l) combinations thereof.
Crystalline Form 1 of sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate (Compound II) characterized as having:
- an XRPD pattern as shown in FIG. 1.
Crystalline Form 1 of sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate (Compound II) characterized as having:
- an XRPD pattern with peaks at about 2.8° 2-Theta, about 7.2° 2-Theta, about 13.4° 2-Theta, about 17.8° 2-Theta, about 19.7° 2-Theta, about 19.9° 2-Theta, and about 20.6° 2-Theta as measured using Cu Kα radiation.
-20. (canceled)
Dependencies are inferred from the claim text.